Labopharm and Angelini announced the launch of Oleptro (trazodone HCl extended-release tablets) for the treatment of major depressive disorder (MDD) in adults. Oleptro is an extended-release formulation of trazodone HCl that utilizes Labopharm’s proprietary Contramid technology to control the release of active ingredients. Oleptro is scored and may be broken in half without compromising the extended-release properties of the tablet due to a membrane that forms across the new inner surface of the broken tablet.
Oleptro is available in 150mg and 300mg dosage strength tablets.
For more information call (877) 345-6177 or visit www.oleptro.com.